<DOC>
	<DOCNO>NCT00635596</DOCNO>
	<brief_summary>This phase I dose escalation study intend define safety , tolerability maximal tolerable dose ( MTD ) MT110 patient advance solid tumor .</brief_summary>
	<brief_title>Phase I Study MT110 Lung Cancer ( Adenocarcinoma Small Cell ) , Gastric Cancer Adenocarcinoma Gastro-Esophageal Junction , Colorectal Cancer , Breast Cancer , Hormone-Refractory Prostate Cancer , Ovarian Cancer</brief_title>
	<detailed_description>MT110 bispecific ( anti-EpCAM x anti-CD3 ) T-cell engager ( BiTE ) design link EpCAM ( epithelial cell adhesion molecule ) express cell T-cells result T-cell activation cytotoxic T-cell response EpCAM+ cell . In vitro ex-vivo data indicate EpCAM+ tumor cell line sensitive MT110 mediate cytotoxicity . Furthermore , data in-vivo experiment MT110 mouse surrogate molecule ( muS110 ) confirm activity molecule inhibit formation metastasis also establish tumor . In vitro ex-vivo data suggest prolonged presence drug target tissue may result significant T-cell recruitment , activation expansion to/in target tissue , potentially result substantial anti-tumor activity man .</detailed_description>
	<criteria>1 . Locally advanced , recurrent metastatic solid tumor know widely express EpCAM proven histology follow entity : Adenocarcinoma lung Small cell lung cancer ( SCLC ) Gastric cancer adenocarcinoma gastroesophageal junction Colorectal cancer ( CRC ) Hormonerefractory prostate cancer ( HRPC ) Breast cancer Ovarian cancer Patients must amenable curative therapy . Patients exhaust declined standard therapeutic option previous therapy include least one course chemotherapy . 2 . Nonmeasurable disease least one measurable tumor lesion per RECIST criterion 3 . Age &gt; /= 18 year 4 . ECOG performance status &lt; /= 2 5 . Life expectancy least 3 month 6 . Must recover acute reversible effect previous anticancer chemotherapy , endocrine therapy , immunotherapy , radiotherapy surgery . This generally mean least 4 week since major surgery , radical radiotherapy myelosuppressive chemotherapy ( 6 week nitrosoureas mitomycin C ) . At least 45 halflives ( t1/2 ) must elapse since treatment investigational agent . At least 4 week since hormonal therapy ( except LHRH agonists patient HRPC ) prior initiate MT110 treatment . 7 . Ability understand patient information inform consent form 8 . Signed date write informed consent 1 . Evidence central nervous system ( CNS ) metastases baseline computer tomography ( CT ) magnetic resonance imaging ( MRI ) scan ( mandatory patient ) , current past relevant history CNS pathology ( except migraine , headache minor incidental finding MRI without clinical manifestation within last five year ) . All minor incidental finding discuss Sponsor 's Medical Monitor ) . 2 . Neutrophil count &lt; 1,500/mm3 ( = 1.5 x 10^9/l ) 3 . Platelet count &lt; 100,000/mm3 ( = 100 x 10^9/l ) 4 . White blood cell ( WBC ) &lt; 3 x10^9/l 5 . Hemoglobin &lt; 9.0 g/dl 6 . Abnormal renal hepatic function define : Alkaline phosphatase ( AP ) &gt; /= 2.5 x upper limit normal ( ULN ) and/or aspartate aminotransferase ( AST , SGOT ) , alanin aminotransferase ( ALT , SGPT ) &gt; /= 2.0 x ULN AP , AST and/or ALT &gt; /= 3 x ULN case liver metastasis ; Î³glutamyl transpeptidase ( GGT ) &gt; /= 5.0 x ULN Total bilirubin &gt; /= 1.5 x ULN Creatinine clearance &lt; 50 ml/min calculate CockroftGault formula MDRD ( modification diet renal disease ) Lipase/amylase &gt; 1.5 x ULN Ddimer &gt; /= 10 x ULN Antithrombin activity &lt; 70 % International normalize ratio ( INR ) &gt; ULN Partial thromboplastin time ( PTT ) &gt; ULN 7 . Oxygen ( O2 ) saturation &lt; 92 % ( room air condition ) 8 . Any concurrent antineoplastic therapy exception radiotherapy palliation symptom agreement Sponsor 's Medical Monitor . No radiation allow define measurable lesion accord RECIST . Patients HRPC receive LHRHagonist therapy &gt; 1 month , continue agonist therapy . 9 . Any concurrent disease , medical social condition could affect compliance protocol interpretation result judge investigator . In particular , patient follow condition allow enter study : Autoimmune inflammatory disease include vasculitis , rheumatoid arthritis , systemic lupus erythematosus ( SLE ) , multiple sclerosis similar condition Active infection know bacteremia Known infection human immunodeficiency virus ( HIV ) chronic infection hepatitis B virus hepatitis C virus Severe dyspnea pulmonary dysfunction need continuous supportive oxygen inhalation Insufficient cardiac function define NYHA ( New York Heart Association ) Grade 3 4 History acute chronic pancreatitis 10 . Chronic systemic corticosteroid therapy longer 2 month immunosuppressive therapy stemcell transplantation . 11 . Presence human antimurine antibody ( HAMA ) know hypersensitivity immunoglobulins ingredient infusion solution . 12 . Pregnant , nursing woman woman childbearing potential willing use effective form contraception participation study least three month thereafter . 13 . Male patient partner childbearing potential willing use effective contraception trial least three month thereafter , unless surgically sterile .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>MT110</keyword>
	<keyword>solid tumor</keyword>
	<keyword>phase I</keyword>
	<keyword>BiTE</keyword>
	<keyword>bispecific T-cell engager</keyword>
</DOC>